Therapy extended median survival to 6.4 months. Two patients are alive four years after start of epigenetic treatment. AACR will host teleconference on Nov. 9, 2011, at 11:00 a.m. ET. PHILADELPHIA — Patients with recurrent metastatic non-small cell...
Filed under: Press Releases, Research, Treatment, Cancer, teleconference, Media Materials, AACR, lung cancer, American Association for Cancer Research, Cancer Discovery, award, Stand Up To Cancer, SU2C, journal, press conference, non-small cell lung cancer, Metastatic, entinostat, epigenetic therapy, azacitidine